Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akero Therapeutics
Biotech
Novo inks $4.7B Akero buyout to bag late-phase MASH prospect
At $54 a share, the upfront deal value represents a 19% premium to Akero’s average stock price over the past 30 days.
Nick Paul Taylor
Oct 9, 2025 8:21am
Apple Tree lawsuit says portfolio biotechs face collapse
Jun 30, 2025 3:21pm
Akero's stock doubles as midphase MASH trial hits the mark
Jan 27, 2025 8:31am
As Madrigal lands MASH nod, what's next for biotechs in pursuit?
Mar 15, 2024 10:55am
Akero soars as liver scarring improves in longer MASH trial
Mar 4, 2024 6:30am
Akero's NASH miss drags a few peers down, spurring deja vu
Oct 11, 2023 10:50am
